| ARCHETYPE ID | openEHR-EHR-OBSERVATION.hscore.v0 |
|---|---|
| Concept | HScore |
| Description | Estimate an individual's risk of having reactive hemophagocytic syndrome. |
| Use | Use to record an estimation of an individual's risk of having reactive hemophagocytic syndrome. |
| Purpose | To record an estimation of an individual's risk of having reactive hemophagocytic syndrome. |
| References | Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C, Chahwan D, Coppo P, Hejblum G. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014 Sep;66(9):2613-20. doi: 10.1002/art.38690. PubMed PMID: 24782338. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 16;. doi: 10.1016/S0140-6736(20)30628-0. [Epub ahead of print] PubMed PMID: 32192578. |
| Authors | Author name: Liv Laugen Organisation: Oslo universitetssykehus Email: liv.laugen@ous-hf.no Date originally authored: 2020-03-30 |
| Other Details Language | Author name: Liv Laugen Organisation: Oslo universitetssykehus Email: liv.laugen@ous-hf.no Date originally authored: 2020-03-30 |
| Other Details (Language Independent) |
|
| Keywords | HLH, Hemophagocytic lymphohistiocytosis, COVID-19, infection, |
| Lifecycle | in_development |
| UID | 677a2484-3ebd-49c9-81fc-b8341fae7a33 |
| Language used | en |
| Citeable Identifier | 1246.145.2770 |
| Revision Number | 0.0.1-alpha |
| protocol | |
| Extension | Extension: Additional information required to extend the model with local content or to align with other reference models or formalisms.
For example: local information requirements; or additional metadata to align with FHIR. Include: All not explicitly excluded archetypes |
| data | |
| Temperature | Temperature: Range category for the body temperature measurement. 0: <38.4°C [The body temperature of the individual is less than 38.4°C.] 33: 38.4-39.4°C [The body temperature of the individual is between 38.4 and 39.4°C.] 49: >39.4°C [The body temperature of the individual is greater than 39.4°C.] |
| Organomegaly | Organomegaly: Findings of any enlargement of the liver or/and spleen in the individual. 0: None [No enlargement of the liver or the spleen.] 23: Hepatomegaly or splenomegaly [Enlargment of the liver or the spleen.] 38: Hepatomegaly and splenomegaly [Enlargement of both the liver and the spleen.] |
| Number of cytopenias | Number of cytopenias: Number of cytopenias present - in red cells, white cells and/or platelets. Defined as either haemoglobin concentration of 9.2 g/dL or less (≤5.71 mmol/L), a white blood cell count of 5000 white blood cells per mm³ (5,0 x 10E9/L) or less, or platelet count of 110 000 platelets per mm³ (110 x 10E9/L) or less, or all of these criteria combined. 0: One lineage [Cytopenia in only one cell lineage.] 24: Two lineages [Cytopenia in two cell lineages.] 34: Three lineages [Cytopenia in three cell lineages.] |
| Triglycerides | Triglycerides: The triglycerides category, measured in mmol/L or mg/dL. 0: <1.5 mmol/L [The Triglyceride level is less than 1.5 mmol/L or 132.7 mg/dL.] 44: 1.5-4.0 mmol/L [The Triglyceride level is 1.5-4.0 mmol/L or 132.7-354 mg/dL.] 64: >4.0 mmol/L [The Triglyceride level is greater than 4.0 mmol/L or 354 mg/dL.] |
| Fibrinogen | Fibrinogen: The fibrinogen category, measured in g/L or mg/dL. 0: >2.5 g/L [The fibinogen level is greater than 2.5 g/L or 250 mg/dL.] 30: ≤2.5 g/L [The fibinogen level is less than or equal to 2.5 g/L 250 mg/dL.] |
| Ferritin | Ferritin: The ferritin category, measured in ng/mL or μg/L. 0: <2000 ng/ml [The ferritin level is less than 2000 ng/ml or 2000 μg/L.] 35: 2000–6000 ng/ml [The ferritin level is 2000-6000 ng/ml or 2000-6000 μg/L.] 50: >6000 ng/ml [The ferritin level is greater than 6000 ng/ml or 6000 μg/L.] |
| Aspartate aminotransferase | Aspartate aminotransferase: An individvals serum aspartate aminotransferase level measured in U/L. This is also known as AST, AspAT, ASAT, AAT or SGOT. 0: <30 U/L [The aspartate aminotransferase level is less than 30 U/L.] 19: ≥30 U/L [The aspartate aminotransferase level is greater than or equal to 30 U/L.] |
| Haemophagocytosis on bone marrow aspirate | Haemophagocytosis on bone marrow aspirate: Presence of hemophagocytosis features in bone marrow aspirate. 0: No [No hemophagocytosis features are present in bone marrow aspirate.] 35: Yes [Hemophagocytosis features are present in bone marrow aspirate.] |
| Known immunosuppression | Known immunosuppression: Presence of known underlying immunosuppression. For example HIV positive or receiving long-term immunosuppressive therapy. 0: No [No known underlying immunosuppression.] 18: Yes [Known underlying immunosuppression.] |
| Total HScore | Total HScore: The total sum for each component variable for the HScore. min: >=0; max: <=337 |
| Probability of HS | Probability of HS: Probability of an individual having reactive hemophagocytic syndrome. According to table 5 in the original original paper by Fardet et al, https://doi.org/10.1002/art.38690.
|
| events | |
| Any event | Any event: Default, unspecified point in time or interval event which may be explicitly defined in a template or at run-time. |
| Other contributors | Heather Leslie, Atomica Informatics, Australia (openEHR Editor) Vebjørn Arntzen, Oslo university hospital, Norway Silje Ljosland Bakke, Helse Vest IKT AS, Norway Marit Alice Venheim, Helse Vest IKT AS, Norway |
| Translators |